BrainStorm Cell Therapeutics Inc. (BCLI) Enters MOU with University of Massachusetts Medical School and Massachusetts General Hospital for ALS Human Trials in US
BrainStorm Cell Therapeutics Inc., a clinical-stage biotechnological company developing noncontroversial, adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of chronic, life-threatening neurodegenerative disorders, has announced that it has signed a Memorandum of Understanding with Massachusetts General Hospital and the University of Massachusetts Medical School in anticipation to apply for FDA approval to commence ALS human clinical trials in the U.S. The parties have agreed to take on initial preparatory steps for the partnership, which includes developing a protocol for the ALS human clinical trials and the selection of the appropriate facilities for production…